Roth Capital Issues Pessimistic Estimate for Joint Earnings

The Joint Corp. (NASDAQ:JYNT) – Stock analysts at Roth Capital reduced their Q4 2025 EPS estimates for Joint in a research report issued on Thursday, November 6th. Roth Capital analyst G. Kelly now anticipates that the company will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.15. The consensus estimate for Joint’s current full-year earnings is $0.11 per share.

Several other equities analysts have also commented on the stock. B. Riley lowered shares of Joint from a “buy” rating to a “hold” rating in a research note on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Joint in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.00.

Joint Stock Performance

Shares of NASDAQ JYNT opened at $8.15 on Monday. The stock’s 50-day simple moving average is $9.08 and its 200-day simple moving average is $10.30. The firm has a market capitalization of $125.05 million, a PE ratio of -24.70 and a beta of 1.48. Joint has a fifty-two week low of $7.50 and a fifty-two week high of $13.47.

Joint (NASDAQ:JYNT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. The company had revenue of $13.38 million for the quarter, compared to analysts’ expectations of $13.36 million. Joint had a positive return on equity of 0.60% and a negative net margin of 7.02%.

Hedge Funds Weigh In On Joint

A number of hedge funds have recently modified their holdings of JYNT. Nisa Investment Advisors LLC raised its position in Joint by 5,141.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,254 shares of the company’s stock valued at $26,000 after purchasing an additional 2,211 shares during the last quarter. JPMorgan Chase & Co. grew its position in Joint by 32.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock worth $86,000 after purchasing an additional 1,810 shares during the last quarter. MetLife Investment Management LLC acquired a new position in Joint in the first quarter valued at $88,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Joint by 25.9% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock valued at $95,000 after buying an additional 1,698 shares during the last quarter. Finally, Stoneridge Investment Partners LLC purchased a new stake in shares of Joint in the third quarter valued at about $117,000. 76.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Christopher M. Grandpre acquired 14,388 shares of Joint stock in a transaction on Friday, August 15th. The stock was bought at an average price of $10.88 per share, for a total transaction of $156,541.44. Following the completion of the purchase, the director owned 19,383 shares in the company, valued at $210,887.04. This represents a 288.05% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 34,388 shares of company stock worth $367,641 over the last quarter. Insiders own 27.90% of the company’s stock.

About Joint

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.